Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2019-09-11

Original market date: See footnote 1

2015-11-09

Product name:

TEVA-ESOMEPRAZOLE

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02423863

Product Monograph/Veterinary Labelling:

Date: 2022-05-20 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

TEVA CANADA LIMITED
30 Novopharm Court
Toronto
Ontario
Canada M1B 2K9

Class:

Human

Dosage form(s):

Tablet (Delayed-Release)

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

56:28.36 

Anatomical Therapeutic Chemical (ATC): See footnote 4

A02BC05 ESOMEPRAZOLE

Active ingredient group (AIG) number:See footnote5

0145162002

List of active ingredient(s)
Active ingredient(s) Strength
ESOMEPRAZOLE (ESOMEPRAZOLE MAGNESIUM DIHYDRATE) 40 MG
Version 4.0.2
Date modified: